Post-Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

Area of Science:

• Hematopoietic Stem Cell Transplantation
• Immunology
• Oncology

Background:

• Post-transplant cyclophosphamide (PT-CY) is standard for GvHD prophylaxis in haploidentical HCT.
• Limitations of PT-CY include relapse, delayed immunity, infections, and organ toxicity.

Purpose of the Study:

• To investigate post-transplant bendamustine (PT-BEN) as a novel GvHD prophylaxis.
• To compare PT-BEN's efficacy and safety against PT-CY in preclinical models and early clinical trials.

Main Methods:

• Evaluation in haploidentical murine and humanized xenogeneic models.
• Phase I clinical trial of a PT-CY/PT-BEN partial substitution platform.
• Immune profiling and toxicity assessment.

Main Results:

• PT-BEN demonstrated uncoupled GvHD and GvL effects in mice, preserving innate immunity.
• PT-BEN with calcineurin inhibition showed superior survival in xenogeneic models.
• Phase I trial indicated safety, accelerated recovery, reduced chronic GvHD, and improved GvHD-free relapse-free survival.

Conclusions:

• PT-BEN presents a mechanistically distinct strategy for GvHD prophylaxis.
• Early clinical data suggest potential benefits over PT-CY, warranting further investigation.
• A multicenter randomized trial is essential to validate PT-BEN's role in HCT outcomes.